ALERT:

Crohn’s Disease Clinical Trial 20193192

[LCID Study Number: 20193192]

A Multicenter, Randomized, Double-blind, Placebo-Controlled study of Efficacy + Safety of Upadacitinib (ABT-494) in subjects with moderately to Severely Active Crohn's Disease who have Inadequately Responded to or Are Intolerant to Biologic Therapy

The purpose of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in subjects with moderately and severely active Crohn’s disease who have inadequately responded to or are intolerant to biologic therapy.

Disease/Condition: Crohn’s Disease

Department: Gastroenterology

Status: Active, Not Recruiting

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734

Protocol #: 20193192
Principal Investigator(s): Randall Pellish
Study Coordinator(s): Deborah Gannon
Trial Phase: Sponsor Initiated Study Phase 3